February Newsmakers

February 10, 2019
By: Julie Poucher Harbin, Writer, DCI

Better breast cancer screening, treatments may have saved hundreds of thousands of lives over 30 years (Reuters)
Features Jay Baker, MD

Duke recreational therapist goes above and beyond for cancer patients (WNCN)
Features Tiffany Atkinson, MS, LRT-CTRS

Sunday Salute: Ashley Linden dealt with cancer by helping others (Fayetteville Observer)
Features Duke Cancer patient and DCI blog

Colon Cancer Screening Controversy. Here's What All The Debate Is About (Forbes)
Features Peter Ubel, MD

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer (Uro Today)
Features Andrew Armstrong, MD

Doctors share cancer screening information (The Wilson Times)
Features Betty Tong, MD; Tian Zhang, MD

Safety Of Flame Retardants Called Into Question (WCAI)
Features Kate Hoffman, PhD

Cancer Patients 10 Times Less Likely To Die From Overdose (Clinical Oncology News)
Features Fumiko Chino, MD

With Blue Cross grant, Duke taps patient partnership app to take on opioid abuse (Mobi Health News)
Features Arif Kamal, MD

Coping With the Emotional Side Effects of AML (Patient Empowerment Network)
Features Thomas LeBlanc, MD 

Hormonal Agents Induce Improved OS in African Americans With Chemo-Naive mCRPC (OncLive)
Features Megan McNamara, MD

Romiplostim Classification and Mechanism of Action (OncLive)
Features Ivy Altomare, MD

Up-front Therapy With Carfilzomib in Myeloma (OncLive)
Cristina Gasparetto, MD

Further Evidence Needed Supporting Clinical Utility of Liquid Biopsies in GI Cancers (OncLive)
Features John Strickler, MD

WATCH: Dr. Brander fshared her message with us in honor of World Cancer Day. What would you want to say to experts changing the treatment paradigm for CLL or other cancers? (Targeted Oncology/Twitter video)
Features Danielle Brander, MD

Differences in Treatment Facilities, Histology Account for Survival Disparities in NSCLC (Targeted Oncology)
Features Jeffrey Crawford, MD

A Look at Therapy Toxicities & Biology in Head & Neck Cancers (Oncology Times)
Features Yvonne Mowery, MD, PhD

Do all chemotherapies have equal long-term heart risk? (Science Daily)
Features Kevin Oeffinger, MD

Frederick National Laboratory, Duke partner to fight brain cancer (The Frederick News Post)
Features Matthias Gromeier, PhD

2019 Edward Novitski Prize awarded to Joseph Heitman (Duke University School of Medicine)
Joseph Heitman, MD, PhD 

A line of promising cancer drugs mysteriously failed in the 90s. Duke researchers may now know why (The Chronicle)
Features Laura Kelly, PhD

Brain Tumor 'Pied Piper' Device Gains Breakthrough Status (Pratt School of Engineering)
Features Ravi Bellamkonda, PhD

'Accidental discoveries': Cancer medications may have other uses (The Chronicle)
Features Ann Marie Pendergast, PhD

Newly Recruited Faculty Bring Expertise in Key Research Areas (Duke University School of Medicine)
Features Andrew West, PhD

Nurses turn end of treatment into a party for pediatric patients (Duke Department of Pediatrics)

Light and Sound Gauge the Temperature of Deep Tissues (Pratt School of Engineering)
Junjie Yao, PhD

PAPERS:

A National Analysis of Long-term Survival Following Thoracoscopic Versus Open Lobectomy for Stage I Non-small-cell Lung Cancer. Annals of Surgery. January 2019. Yang, Chi-Fu Jeffrey, MD; Kumar, Arvind, BS; Klapper, Jacob A., MD; Hartwig, Matthew G., MD, MHS; Tong, Betty C., MD, MHS; Harpole, David H. Jr., MD; Berry, Mark F., MD, MHS; D’Amico, Thomas A., MD.

Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity. JAMA Oncology. January 31, 2019.  Elizabeth A. M. Feijen, PhD; Wendy M. Leisenring, ScD; Kayla L. Stratton, MS; Kirsten K. Ness, PT, PhD; Helena J. H. van der Pal, MD, PhD; Elvira C. van Dalen, MD, PhD1; Gregory T. Armstrong, MD, MSCE; Gregory J. Aune, MD, PhD; Daniel M. Green, MD; Melissa M. Hudson, MD; Jacqueline Loonen, MD, PhD; Kevin C. Oeffinger, MD; Leslie L. Robison, PhD; Yutaka Yasui, PhD; Leontien C. M. Kremer, MD, PhD; Eric J. Chow, MD, MPH.

N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway. Molecular Cancer. January 2019. Yu Yin, Lingfan Xu, Yan Chang, Tao Zeng, Xufeng Chen, Aifeng Wang, Jeff Groth, Wen-Chi Foo, Chaozhao LiangEmail author, Hailiang HuEmail author and Jiaoti Huang